Alendronic Acid Weekly
Brand names: Fosamax Once Weekly, Binosto
This is the once-weekly oral alendronic acid formulation, an equivalent bisphosphonate regimen to daily dosing used for osteoporosis treatment and prevention, designed to improve adherence and reduce dosing frequency.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Like daily alendronate it binds bone mineral and inhibits osteoclast farnesyl pyrophosphate synthase, suppressing bone resorption; the larger weekly dose maintains the same antiresorptive effect.
Prescribing in practice
- The same strict administration rules apply on the chosen weekly dosing day: take on rising with plain water and remain upright without food or other medicines until after the post-dose interval, as oesophageal injury risk is the key hazard.
- If a weekly dose is missed it should be taken the next morning and the patient should then return to the original chosen day, not double up.
- Ensure calcium and vitamin D sufficiency and counsel on the rare risks of osteonecrosis of the jaw and atypical femoral fracture.
Monitoring
Monitor renal function and calcium, and periodically reassess fracture risk and the case for a treatment break after extended use.
Counselling the patient
- Take it on the same chosen day each week, first thing with plain water, then stay upright and avoid food and other tablets until after the interval.
- If you forget, take it the next morning and then go back to your usual day.
- Report swallowing problems, heartburn or new thigh or groin pain, and keep up good dental care.
Evidence & guidelines
Weekly dosing was shown to be therapeutically equivalent to daily alendronate on bone density and is endorsed within NICE osteoporosis guidance.
Reference: NICE NG187; RCP guidelines; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Falls Assessment in Older Adults · NICE CG161 2013
- Delirium Outside ICU · NICE CG103
- Comprehensive Geriatric Assessment (CGA) · BGS / NICE
- Delirium Assessment and Management · NICE CG103 2010
- Frailty Recognition and Management · BGS Frailty Framework / NHS NHSE
- Polypharmacy and Medicines Optimisation · STOPP/START v2 2014 / NICE NG5